KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin (2016 - 2026)

TherapeuticsMD filings provide 16 years of FCF Margin readings, the most recent being 130.39% for Q1 2026.

  • On a quarterly basis, FCF Margin fell 4748.0% to 130.39% in Q1 2026 year-over-year; TTM through Mar 2026 was 80.5%, a 3346.0% decrease, with the full-year FY2025 number at 81.2%, up 1476.0% from a year prior.
  • FCF Margin hit 130.39% in Q1 2026 for TherapeuticsMD, up from 41.99% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5004.52% in Q3 2022 to a low of 11373.58% in Q3 2023.
  • Median FCF Margin over the past 5 years was 2.55% (2024), compared with a mean of 1038.33%.
  • Biggest five-year swings in FCF Margin: tumbled -1637810bps in 2023 and later skyrocketed 1136061bps in 2024.
  • TherapeuticsMD's FCF Margin stood at 44.1% in 2022, then tumbled by -2341bps to 988.05% in 2023, then soared by 100bps to 2.55% in 2024, then surged by 1548bps to 41.99% in 2025, then skyrocketed by 210bps to 130.39% in 2026.
  • The last three reported values for FCF Margin were 130.39% (Q1 2026), 41.99% (Q4 2025), and 127.42% (Q3 2025) per Business Quant data.